$ Value
$0
Shares
64,900
Price
$0
Filed
Jan 6
Insider
Name
Nayak Sanjay
Title
Chief Strategy Officer
CIK
0002012715
Roles
Transaction Details
Transaction Date
2026-01-02
Code
A
Table
Non-Derivative
Ownership
Direct
Equity Swap
No
Shares After
342,760
Footnotes
On January 2, 2026, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Corporation"). Each RSU represents a right to receive one share of the Corporation's common stock. Subject to the reporting person's continued service to the Corporation, the RSUs will vest over three years, with 1/3 of the shares underlying the RSUs vesting on the one-year anniversary of the date of grant and an additional 1/3 of the shares underlying the RSUs vesting at the end of each successive one-year period thereafter. | Subject to the reporting person's continued service to the Corporation, the shares underlying this option vest over four years, vesting 1/48 monthly beginning on the one-month anniversary of the date of grant.
Filing Info
Nayak Sanjay's History
| Date | Ticker | Type | Value |
|---|---|---|---|
| 2026-02-23 | OCUL | ▼ | $15K |
| 2026-02-12 | OCUL | ▼ | $94K |
| 2026-01-02 | OCUL | A | $0 |
| 2026-01-02 | OCUL | A | $0 |
| 2025-11-24 | OCUL | ▼ | $23K |
| 2025-08-25 | OCUL | ▼ | $23K |
| 2025-05-23 | OCUL | ▼ | $13K |
Other Insiders at OCUL (90d)
| Insider | Bought | Sold | Last |
|---|---|---|---|
| LINDSTROM RICHARD L MD | $461K | — | 2026-02-20 |
|
Heier Jeffrey S.
Chief Scientific Officer
|
— | $25K | 2026-02-23 |
|
Dugel Pravin
See Remarks
|
— | $1.3M | 2026-04-09 |
|
Notman Donald
Chief Operating Officer
|
— | $205K | 2026-02-12 |
|
Kaiser Peter
Chief Development Officer
|
— | $23K | 2026-02-23 |
|
Nayak Sanjay
Chief Strategy Officer
|
— | $108K | 2026-02-23 |
|
Waheed Nadia
Chief Medical Officer
|
— | $98K | 2026-02-20 |
|
Robinson David Wayne
Global CCO
|
— | — | 2026-01-21 |